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ORIGINAL RESEARCH
Chronic Disease Burden After Congenital 
Heart Surgery: A 47- Year Population- Based 
Study With 99% Follow- Up
Alireza Raissadati , MD, PhD; Jari Haukka, MD, PhD; Tommi Pätilä, MD, PhD; Heta Nieminen, MD, PhD;  
Eero Jokinen, MD, PhD
BACKGROUND: Postoperative morbidity is an increasingly important outcome measure of patients who have undergone con-
genital heart surgery (CHS). We examined late postoperative morbidity after CHS on the basis of patients’ government- issued 
medical special reimbursement rights.
METHODS AND RESULTS: Between 1953 and 2009, 10 635 patients underwent CHS at <15 years of age in Finland. We 
excluded early deaths and mental disabilities. Noncyanotic and cyanotic defects were divided into simple and severe 
groups, respectively. We obtained 4 age- , sex- , birth time–, and hospital district–matched control subjects per patient. 
The Social Insurance Institution of Finland provided data on all medical special reimbursement rights granted between 
1966 and 2012. Follow- up started at the first operation and ended at death, date of emigration, or December 31, 2012. A 
total of 8623 patients met inclusion criteria. Follow- up was 99.9%. A total of 3750 patients (43%) required special reim-
bursements rights for a chronic disease. Cardiovascular disease was the most common late morbidity among patients 
(28%), followed by obstructive pulmonary disease (9%), neurologic disease (3%), and psychiatric disease (2%). Heart 
failure (simple hazard ratio [HR], 56.3 [95% CI, 35.4–89.7]; severe HR, 918.0 [95% CI, 228.9–3681.7]) and arrhythmia 
(simple HR, 11.0 [95% CI, 7.1–17.0]; severe HR, 248.0 [95% CI, 61.3–1002.7]) were the most common cardiovascular 
morbidities. Hypertension was common among patients with coarctation of the aorta (13%; incidence risk ratio [RR], 
8.9; 95% CI, 7.5–10.7). Psychiatric disease was more common among simple defects, particularly ventricular septal 
defects.
CONCLUSIONS: Chronic cardiac and noncardiac sequelae are common after CHS regardless of the severity of the defect, un-
derscoring the importance of long- term follow- up of all patients after CHS.
Key Words: congenital heart disease ■ epidemiology ■ morbidity ■ outcome ■ pediatric cardiology
Congenital heart defects (CHDs) are the most common single- organ malformations, with a worldwide incidence of 9 to 13 of 1000 births 
annually.1 In Finland, ≈1% of children are born with 
a CHD, of whom 60% require either surgical- or 
catheter- based correction or palliation. Previous 
register- based studies have established the im-
proved operative mortality and late survival of this 
growing patient population.2 The increasing number 
of patients surviving to adulthood, however, neces-
sitates more focus on their morbidity and quality of 
life as measures of the quality of care and outcome. 
We previously established that, although overall sur-
vival has improved, patients remain at risk for prema-
ture death attributable to both cardiac- related and 
nonrelated causes, underlining the importance of 
long- term follow- up regardless of the severity of the 
defect.3,4
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In the current study, we combined data from 4 
Finnish national registries to obtain a comprehensive 
profile of the postoperative morbidity of patients over 
a 5- decade time period in hopes of establishing the 
importance of postoperative follow- up of this patient 
group. Chronic morbidity was indirectly assessed by 
examining special reimbursement rights issued by 
the Finnish government to cover the cost of long- term 
medications for Finnish citizens.
METHODS
The Finnish Ministry of Social Affairs and Health granted 
permission for this study, and the ethical committee 
approved the research protocol. The data that sup-
port the findings of this study are available from the 
author Tommi Pätilä (tommi.patila@hus.fi) at Helsinki 
University Central Hospital upon reasonable request.
Patients and Data Collection
We obtained patient and operative data from the 
custom- built ProCardio version 8 (Research Registry 
of Pediatric Cardiac Surgery, Melba Group, Helsinki, 
Finland) database running on Filemaker Pro ver-
sion 8.5 (Filemaker Inc, CA), which stores data on 
all pediatric congenital heart surgeries (CHSs) per-
formed since 1953 in Finland at 5 university hospitals 
(Helsinki, Kuopio, Oulu, Tampere, and Turku) and 1 
regional hospital (Aurora Hospital, Helsinki). Since 
1997, all CHSs have been centralized to Helsinki 
University Central Hospital. We excluded patients 
who underwent closure of a patent ductus arteriosus 
(PDA) at an age of ≤30 days because of the high inci-
dence of prematurity among this population. We also 
excluded isolated pacemaker implantations and pa-
tients with known mental disability. Only patients who 
survived their first operation were included (>30 days 
after the operation). Patient data were obtained from 
January 1966 to December 2009. The later starting 
point was chosen to coincide with the introduction 
of the medical special reimbursement program in 
Finland.
The Finnish Population Registry provided the sta-
tus and time of death for all patients. The causes of 
death were gathered through autopsy reports and 
physician reports on a national scale. Statistics Finland 
supplied us with 4 age- , sex- , birth date–, and hospi-
tal district–matched control subjects per patient, along 
with causes of death for both patients and controls. 
Patients who were not included in the final analyses 
had their respective matched controls removed from 
the data. Informed consent from patients and the gen-
eral population included in this study was waived be-
cause of the retrospective and anonymous nature of 
the investigation.
Every Finnish citizen is reimbursed for medications 
that treat chronic diseases. This reimbursement is 
granted by The Social Insurance Institution of Finland, 
which provides social security benefits to Finnish na-
tionals. Morbidity was assessed by inspecting data 
on patients’ medical special reimbursement entitle-
ments obtained from The Social Insurance Institution 
of Finland. Once a patient is granted a special reim-
bursement right, he/she can purchase the medication 
required for his/her chronic condition and receive sub-
stantial subsidies from the government for it, so that the 
final out- of- pocket amount remains affordable for the 
patient. As such, the special reimbursement right does 
not represent a time point when a patient purchases a 
CLINICAL PERSPECTIVE
What Is New?
• Cardiovascular and noncardiovascular morbid-
ity is more common among patients after con-
genital heart surgery compared with the general 
population, regardless of defect severity.
• Polypharmacy is common among patients, re-
gardless of the severity of the defect.
• Mental disorders are not uncommon among 
patients after congenital heart surgery, particu-
larly among patients with simple defects.
What Are the Clinical Implications?
• Long-term follow-up is essential after congenital 
heart surgery for all defects, regardless of the 
severity of the defect.
• Follow-up in primary care is important to ad-
dress the high incidence of noncardiovascular 
morbidity.
• More emphasis should be placed on mental 
health screening among adults with congeni-
tal heart disease, and mental health services 
should be made readily available for them.
Nonstandard Abbreviations and Acronyms
ASD atrial septal defect
CHD congenital heart defect
CHS congenital heart surgery
COA coarctation of the aorta
HLHS hypoplastic left heart syndrome
PDA patent ductus arteriosus
TGA transposition of the great arteries
TOF tetralogy of Fallot
UVH univentricular heart
VSD ventricular septal defect
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certain medication, but rather the time when the pa-
tient is diagnosed with a disease that grants him/her 
a special reimbursement right. Thus, for the sake of 
statistical analyses, you can use the date a special re-
imbursement right is acquired as the date a patient is 
diagnosed with a disease.
The criteria for special reimbursement entitlements 
depend on the medication and require a signed let-
ter of medical necessity from the patient’s physician 
stating the indication of the drug. Each special reim-
bursement entitlement requires a specific attached 
International Classification of Diseases (ICD) diagnosis 
code. We obtained all special reimbursement entitle-
ments and the associated ICD-9 and ICD-10 diagno-
ses between 1966 and 2012. Diagnoses were placed 
by both primary and specialty healthcare providers 
across the country.
Study Design
Diseases were grouped according to the indication of 
the special reimbursement entitlement, as presented 
in Table S1. Morbidity is presented as incidence of 
selected disease groups and compared between pa-
tients and controls by calculated rate and hazard ra-
tios (HRs). We refrained from comparing time periods 
because of the heavy confounding effect from the 
change in special reimbursement policies throughout 
the years.
For the survival studies, follow- up ended at the 
date of the first special reimbursement entitlement 
within each disease group, death, emigration, or 
December 31, 2012. Each patient was assigned one 
primary diagnosis from a severity- based hierarchi-
cal list of cardiac defects: PDA, atrial septal defect 
(ASD), coarctation of the aorta (COA), ventricular 
septal defect (VSD), tetralogy of Fallot (TOF), trans-
position of the great arteries (TGA), hypoplastic left 
heart syndrome (HLHS), and univentricular heart 
(UVH). All remaining cardiac defects were collec-
tively referred to as miscellaneous, including trun-
cus arteriosus, atrioventricular canal, congenitally 
corrected TGA, pulmonary stenosis, total anoma-
lous pulmonary venous return, partial anomalous 
pulmonary venous drainage, Ebstein anomaly, inter-
rupted aortic arch, isolated valve defects, aortopul-
monary window, vascular ring, trauma, pericardial 
disease, aortic aneurysms, and heart transplants. 
For patients with several cardiac defects, we chose 
the hierarchically more severe condition.5,6 To sim-
plify the analyses, we dichotomized defect severity 
into simple (PDA, ASD, COA, and VSD) and severe 
(TOF, TGA, HLHS, and UVH) defects, according 
to the lack or presence of cyanosis, respectively. 
Detailed operative data for select defects are pre-
sented in Table S2.
Statistical Analysis
Incidence risk ratios (RRs) were obtained using 
Poisson regression with 95% CIs and were based 
on incidence rates of first events. HRs were ob-
tained using matching group stratified Cox regres-
sion models. The matching reference units were 
accounted for as strata in the Cox model. Survival 
data are presented in the form of Kaplan- Meier 
plots. We used the date the first special reimburse-
ment right for each disease group was granted as 
the event of interest. Death and emigration were 
treated as censoring events, such that special reim-
bursements were treated as events of interest until 
the day of death or emigration. Two- tailed P values 
were obtained with the log- rank test. In the esti-
mation of hazard rate curves, we used Poisson re-
gression with splines to produce smoothed curves 
with a 95% confidence envelope. We used B- spline 
basis matrix for a natural cubic spline with knots 
at 5, 15, 25, 35, and 45  years. SDs are reported 
with mean values. Analyses were performed using 
R program with the Epi package (R Development 
Core Team, Vienna, Austria, 2011) and IBM SPSS 
Statistics version 25.0 (SPSS, Inc, Chicago, 
IL).
RESULTS
Patients
After excluding PDA operations at <30  days of life, 
we identified 10  635 patients who underwent CHS 
between 1953 and 2009. After excluding early deaths 
(<30 days after first operation), patients with known 
intellectual disabilities, and all patients who under-
went CHS before 1966, 8631 patients remained. 
Eight patients were excluded because of insufficient 
data. Thus, follow- up coverage was practically 100% 
with 8623 patients (Figure 1). Mean length of follow-
 up to death or end of the study was 23  years (SD, 
±12.1 years; Table  1). The mean age at the end of 
follow- up was 26.6 years (SD, ±14.2 years; Table 1) 
for all patients.
The sex ratio was equal among simple and mis-
cellaneous defects but male dominant among severe 
defects (Table 1). Mean age at the first operation was 
4.2 years among simple defects and 1.4 years among 
severe defects (Table 1). Of patients who survived their 
operation, 6% died during their subsequent follow- up 
(Table  1). The cause of death was defect related in 
49% of cases in the simple group (133/270) and 87% 
of cases in the severe group (234/263) (Table 1). The 
most common defect- related cause of death was 
heart failure in both groups (44% simple and 36% se-
vere; Table 1).
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Chronic Morbidity and Need for 
Medications
A total of 3750 patients (43%) had a chronic disease 
with an entitlement to special reimbursements for 
their medication. Results of the most common spe-
cial reimbursement groups are presented by defect 
severity in Figure  2 and by subgroups in Table  2. 
The absolute numbers of patients with special reim-
bursements are detailed in Table S3. Cardiovascular 
disease was the most common indication for spe-
cial reimbursement rights among patients (RR, 11.5 
versus controls; 95% CI, 10.5–12.7), followed by ob-
structive pulmonary disease (RR, 1.8 versus controls; 
95% CI, 1.6–1.9), endocrine disease (RR, 2.0 versus 
controls; 95% CI, 1.7–2.2), neurologic disease (RR, 
2.5 versus controls; 95% CI, 2.1–2.9), and psychiatric 
disease (RR, 1.3 versus controls; 95% CI, 1.1–1.6). 
Chronic diseases were on average more common in 
the severe group.
Cardiovascular Disease
One fourth (28%) of patients required special reim-
bursement rights for cardiovascular medications 
(18% of patients with simple defects and 53% of 
those with severe defects). Heart failure was the 
most common indication for cardiovascular medica-
tion across all defect groups (Figure 2, Table 2, and 
Table S3). Overall, patients with severe defects were 
at a higher risk of heart failure compared with those 
with simple defects (Figure 2 and Table 2). One fifth 
(20%) of patients required medication for heart failure 
(12% of patients with simple defects, 40% of patients 
with severe defects, and 32% of patients with mis-
cellaneous defects) (Table S3). Patients with univen-
tricular morphological UVH (67%) and HLHS (84%) 
required special reimbursement rights for heart fail-
ure medications most frequently, whereas patients 
with PDA and ASD were at lowest risk (Table  2). 
Freedom from medication for heart failure diminished 
Figure 1. Flowchart of the study patient population.
ASD indicates atrial septal defect; COA, coarctation of the aorta; HLHS, hypoplastic left heart syndrome; 
PDA, patent ductus arteriosus; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; UVH, 
univentricular heart defect; and VSD, ventricular septal defect.
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markedly during the first year after the first CHS, with 
30- year survival rates of 60% (95% CI, 57%–63%) 
among severe defects and 95% (95% CI, 94%–95%) 
among simple defects (Figure 3A). The derivative of 
the survival curve (hazard rate curve) for heart failure 
medication was trimodal in the severe group, indicat-
ing a high need for heart failure medication imme-
diately and an estimated 15 and 30  years after the 
first operation (Figure 3B). Furthermore, patients with 
TGA and UVH required medication for heart failure 
on average 6 years (SD, 8.1 years) and 2.5 years (SD, 
5.1 years) after their first operation, respectively.
Hypertension was the second most common indica-
tion for cardiovascular medication after CHS (patients 
versus controls: RR, 2.8; 95% CI, 2.4–3.2). The postop-
erative need for special reimbursement rights to cover 
antihypertensives was highest after surgery for COA 
(13.0%), HLHS (6.2%), and UVH (3.1%). Patients with 
COA who required antihypertensives were on average 
older at their first operation compared with those with-
out antihypertensives (6.0±4.9 versus 3.3±4.9  years, 
respectively; P<0.0001). Freedom from special reim-
bursement rights for antihypertensives at 30  years 
after the first operation was 95% (95% CI, 94%–96%) 
in the simple group and 97% (95% CI, 96%–98%) in 
the severe group (Figure 3A).
Of the patient population, 3% received special re-
imbursement for antiarrhythmics. Patients in all defect 
groups except PDA required special reimbursement 
rights for antiarrhythmics more frequently than the con-
trol population (all patients: RR, 25.7 versus controls; 
95% CI, 18.6–45.0), with a higher incidence in the se-
vere defect group. Among simple defects, patients with 
VSD had the highest RR for antiarrhythmics (Table 2), 
whereas univentricular defects had the highest risk 
among severe defects (HLHS, 8.2%; and UVH, 16.0%). 
The 30- year freedom from reimbursement rights for 
antiarrhythmics among severe defects was 87% (95% 
CI, 85%–90%; Figure 3A). The hazard rate curve for ar-
rhythmia was trimodal in the severe group, with a peak 
of first special reimbursement rights within the first year 
and an estimated 15 to 20 and 25 to 30 years after the 
first operation (Figure 3B). Patients with ASD and COA 
required their first special reimbursement rights for an-
tiarrhythmics an average of >20 years after their first 
operation, whereas patients with VSD, TOF, TGA, and 
UVH required them within an average of 11 to 18 years 
after their first operation.
Obstructive Pulmonary Disease
Obstructive pulmonary disease was the most common 
noncardiovascular indication for special reimburse-
ment rights among patients (9%) and was more com-
mon among simple defects (490/5604; 9%; Table S3). 
Asthma was practically the only indication for special 
Table 1. Patient Characteristics
Characteristic
Defect Group
Simple Severe Miscellaneous
Defects, n (%) 5604 (100) 1440 (100) 1579 (100)
PDA 1522 (27) … …
ASD 1353 (24) … …
COA 1301 (23) … …
VSD 1428 (26) … …
TOF … 587 (41) …
TGA … 499 (34) …
HLHS … 97 (7) …
UVH … 257 (18) …
Miscellaneous … … 1579 (100)
Sex, n (%)
Women 3065 (55) 547 (38) 752 (48)
Men 2539 (45) 893 (62) 827 (52)
Decade of first operation, n (%)
1966–1969 489 (9) 69 (5) 54 (3)
1970–1979 1325 (23) 231 (16) 208 (13)
1980–1989 1378 (25) 334 (23) 346 (22)
1990–1999 1610 (29) 404 (28) 520 (33)
2000–2009 802 (14) 402 (28) 451 (29)
Age at first operation, 
mean±SD, y
4.2±4.0 1.4±2.7 3.5±4.4
<1 mo, n (%) 482 (7) 543 (38) 280 (18)
1–12 mo, n (%) 1335 (24) 462 (32) 494 (31)
1–4 y, n (%) 1335 (24) 267 (18) 275 (17)
>4 y, n (%) 2452 (44) 168 (12) 530 (34)
No. of operations, n (%)
1 3955 (70) 754 (52) …
2 1394 (25) 327 (23) …
3 204 (4) 247 (17) …
>3 49 (1) 110 (8) …
Status, n (%)
Alive 5241 (93) 1168 (81) 1565 (99)
Deceased 270 (5) 263 (18) 14 (1)
Defect related 133 (49) 234 (87) 4 (29)
Unknown 3 (2) 1 (0) 0
Reoperative 30 (23) 65 (28) 0
Cardiovascular 9 (7) 30 (13) 0
Sudden 33 (25) 54 (23) 3 (75)
Heart failure 58 (44) 84 (36) 1 (25)
Non–defect related 137 (51) 29 (13) 10 (71)
Unknown 93 (2) 9 (1) 0
Follow- up, mean±SD, y 25.0±12.0 18.3±11.9 20.6±11.2
Age at end of follow- up, mean±SD, y
Alive 29.6±13.9 21.6±12.6 23.9±13.2
Deceased 21.8±17.2 11.5±12.7 43.2±6.9
All 29.1±14.1 19.7±13.2 24.1±13.3
ASD indicates atrial septal defect; COA, coarctation of the aorta; HLHS, 
hypoplastic left heart syndrome; PDA, patent ductus arteriosus; TGA, 
transposition of the great arteries; TOF, tetralogy of Fallot; UVH, univentricular 
heart defect; and VSD, ventricular septal defect.
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reimbursement rights for obstructive pulmonary dis-
ease and was significantly more common among pa-
tients compared with controls (RR, 1.8; 95% CI, 1.6–1.9 
versus controls). Among simple defects, patients with 
VSD (8.8%) had the highest risk of asthma. Patients 
with HLHS had the highest risk, whereas patients with 
UVH had the highest absolute incidence of special re-
imbursement rights for asthma (8.9%) among severe 
defects. The 30- year freedom from special reimburse-
ment rights for asthma was 91% (95% CI, 90%–92%) 
among simple defects and 91% (95% CI, 89%–92%) 
among severe defects (Figure  3A). The hazard rate 
was highest during the first 5 postoperative years 
(Figure 3B).
Endocrine Disease
All in all, 145 patients (1.7%) had a special reimburse-
ment right for diabetes mellitus. Only patients with ASD 
had a higher risk for diabetes mellitus than the control 
population (Table 2). Patients with severe defects were 
at an increased risk of hypopituitarism (HR, 4.9; 95% 
CI, 3.4–7.2 versus controls), albeit with low absolute 
numbers (Table S3). There was also an increased risk 
for hypopituitarism among patients with ASD (Table 
S3).
Neurologic and Psychiatric Disease
Epilepsy was the most common neurologic indication 
for special reimbursement rights after CHS (Figure 2) 
and overall second most common noncardiovascu-
lar morbidity after CHS among all patients (Table S3). 
Patients with severe defects had a higher risk for re-
quiring special reimbursement rights for epilepsy than 
those with simple defects (HR, 4.0; 95% CI, 2.7–5.9 
versus controls), with 3.8% of patients with TGA, 3.5% 
of patients with UVH, and 8.2% of patients with HLHS 
requiring special reimbursement rights for antiepilep-
tics. VSD had the highest risk of epilepsy among sim-
ple defects (Table 2).
This study does not include antidepressants be-
cause of the lack of a dedicated special reimburse-
ment program. Regardless, patients with VSD required 
special reimbursement rights for psychiatric disease 
more often than the control population, particularly an-
tipsychotics (Table 2). Patients with severe defects did 
not have a higher number of special reimbursements 
Figure  2. The hazard ratio (HR) of selected chronic diseases by defect severity compared with a matched reference 
population.
Results were obtained with a stratified Cox regression model comparing simple and severe patients with 4 sex- , age- , date of birth–, 
and hospital district–matched control subjects. Both the simple and severe defect groups were burdened with significantly more 
cardiovascular and noncardiovascular disease compared with the general population, including epilepsy, asthma, and endocrine 
disorders. *Denotes statistically significant results. ADHD indicates attention deficit hyperactivity disorder.
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Figure  3. Freedom from selected chronic diseases and time- dependent hazard 
rates by defect severity.
A, Kaplan- Meier curves depicting survival free of special reimbursement rights for the 4 
most common indications for long- term medications among patients. B, Hazard rate with 
95% CI for the 4 most common disease groups among patients as a function of time. 
Hazard rates were obtained using Poisson regression model comparing the simple and 
severe groups with 4 sex- , age- , date of birth–, and hospital district–matched control 
subjects. Shaded areas represent 95% CIs.
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for psychiatric medications compared with the control 
population.
Other Disease
Rheumatic disease was more common in the severe 
defect group compared with the control population 
(Figure 2). Patients were not at higher risk for hemato-
logical, dermatological, or inflammatory bowel disease. 
Malignancies were common among both patients and 
the general population, with patients with ASD having a 
higher incidence of cancer than their matched controls 
(data not shown).
Cardiovascular Morbidity by Defect Type 
and Operative Technique
Thirteen percent of all patients with COA who under-
went an end- to- end operation and 10% who under-
went the subclavian flap operation required special 
reimbursement rights for antihypertensives. Of all 
VSD patients, 28% required special reimbursement 
rights for heart failure (26% of patients with single VSD 
and 38% of patients with multiple VSDs). Of all TOF 
patients, 24% required special reimbursement rights 
for heart failure medications (37% of those who un-
derwent staged correction versus 20% of those who 
underwent primary correction). In the TGA group, 24% 
of all patients who underwent an arterial switch opera-
tion (ASO) required special reimbursement rights for 
heart failure medication versus 56% for those who un-
derwent the Mustard operation and 44% who under-
went the Senning. Similarly, only 6% of ASO patients 
required special reimbursement rights for antiarrhyth-
mics (14/250) versus 11% of Mustard (8/73) and 14% of 
Senning patients (17/122).
Cardiovascular Comorbidity
Almost one fifth of patients with UVH (19%) who re-
quired medication for heart failure required treatment 
for coexisting arrhythmia. Similarly, 17% of patients 
with TGA who had an entitlement for heart failure med-
ication also had an entitlement to antiarrhythmic medi-
cations. From another point of view, 80% and 69% of 
patients with UVH and TGA, respectively, who required 
antiarrhythmics also had an entitlement to heart failure 
medication. Similarly, 50% of patients with TOF, 43% 
of patients with VSD, and 60% of patients with COA 
with antiarrhythmics required simultaneous treatment 
for heart failure.
All patients with UVH and 90% of patients with TGA 
who required antihypertensives were also entitled to 
medication for heart failure. Of patients with TOF who 
required antihypertensives, 45% were also entitled to 
medications for heart failure, with a corresponding 
15% rate for patients with COA.
DISCUSSION
In this population- based study, we found that pedi-
atric patients with CHD who underwent CHS were 
at significant risk for late morbidity regardless of the 
severity of their cardiac defect. The need for medica-
tion to treat cardiovascular disease was particularly 
pronounced.
Cardiovascular Morbidity
The higher prevalence of cardiovascular disease in 
the severe defect group was not surprising given the 
higher cardiac strain associated with more compli-
cated defects, residual cardiac abnormalities, multiple 
operations, and complex and prolonged surgery.
Heart failure is a common late sequala among pa-
tients with CHDs and was by far the most common 
chronic morbidity for all cardiac defects.7 A reported 
40% to 50% of patients experience heart failure 
after the Fontan operation, representing the most 
common cause of death among this patient popula-
tion.4,8,9 In this study, the incidence of heart disease 
was proportional to the severity of the defect, with 
most (72%) of patients with single- ventricle physio-
logical features requiring medication for heart failure. 
According to the literature, 40% to 50% of patients 
with TGA who undergo an atrial switch operation ex-
perience right ventricular failure late after surgery.10 In 
our material, over a third of all TGA patients (36%) re-
quired heart failure medication, particularly patients 
who underwent an atrial switch operation (49%). 
The main reason is the abnormal cardiac physiolog-
ical characteristics after the atrial switch operation. 
Patients with VSD are at risk for late aortic valve in-
sufficiency, which may predispose to left ventricular 
strain if left untreated.11 Also, pulmonary hyperten-
sion predisposes to heart failure, which could be the 
case among some patients with VSD operated on 
during the earlier decades. In our material, patients 
with VSD were at highest risk of heart failure (28%) 
among simple defects.
Arrhythmias were common in all defect groups, 
except PDA, the correction of which does not involve 
manipulation of the cardiac tissue. Interestingly, pa-
tients with COA had a higher than expected risk of 
arrhythmia, with no correlation with hypertension 
and operative age. The cause of postoperative ar-
rhythmias is multifactorial and involves damage to 
the cardiac conduction system, tissue hypoxia, pri-
mary myocardial disease, and residual defects.12 
Arrhythmia and sudden deaths are recognized late 
complications after CHS, with >50% of all patients de-
veloping atrial arrhythmias before the age of 65 years 
and an overall increase in the cumulative risk with ad-
vanced age.13 Previous studies have established the 
high incidence of arrhythmias in patients with TGA 
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who undergo atrial correction, with a corresponding 
low incidence among patients who undergo the ASO 
because of the lack of right atrial manipulation.14,15 In 
the current study, we observed that a lower propor-
tion of patients with TGA who underwent ASO re-
quired antiarrhythmics postoperatively versus those 
who underwent an atrial switch operation. These 
results reflect those from our previous study, where 
we found that the switch to using the ASO method 
was paralleled by a decrease in the incidence of sud-
den deaths compared with the Senning and Mustard 
techniques.4 However, the shorter follow- up time of 
patients who underwent the ASO must be taken into 
account when interpreting these results. Patients 
with Fontan circulation have a reported 7% to 39% 
prevalence of postoperative arrhythmia.16 In the cur-
rent study, patients with single- ventricle defects had 
the highest need for antiarrhythmics, at a prevalence 
of 14%.
Patients with CHD are at risk of increased arterial 
stiffness.17,18 Häcker et al18 reported a significant cor-
relation between low physical activity and increased 
arterial stiffness among this patient population, inde-
pendent of the body mass composition. Moreover, 
studies have established a high prevalence of obesity 
among CHD patients, placing these patients at risk for 
metabolic syndrome.19,20 Accordingly, we observed an 
increased risk of hypertension among patients with 
COA, PDA, and HLHS. Recurrent hypertension is a 
common late sequala after surgery for COA, with re-
ports of a 30% to 75% postoperative prevalence.21,22 
In our material, 13% of patients required antihyperten-
sives after correction of COA at an average of 24 years 
after their surgery.
Noncardiovascular Morbidity
Obstructive pulmonary disease was the most common 
noncardiovascular late morbidity after CHS in terms 
of absolute numbers. We strived to minimize the ef-
fect of prematurity on the results by excluding patients 
who underwent PDA ligation within the first month of 
life. Nevertheless, this method did not necessarily re-
move all patients who were born prematurely, which 
could potentially explain the higher incidence of ob-
structive airway disease among patients. Studies have 
suggested the coexistence of asthma among CHD 
patients, and possible misdiagnosis of pulmonary hy-
pertension as asthma.23–26 An alternative explanation 
for the higher prevalence of obstructive airway disease 
is misdiagnosis of cardiac asthma as reactive airway 
disease, higher incidence of mechanical ventilation, or 
low birth weight.
The risk for late neurological sequalae, particularly 
epilepsy, among the CHD population is well estab-
lished.27,28 In our material, epilepsy was the second 
most common noncardiovascular late complication 
after CHS, despite excluding mentally disabled pa-
tients. Neurological complications have been associ-
ated even with nonoperated CHD patients and have 
been connected to potential abnormal regulation of 
prenatal cerebral oxygen supply.27 Also, de novo gene 
mutations may play a role in the neurodevelopmental 
outcome of these patients.29
Psychiatric disorders were more common 
among patients with simple defects, particularly 
VSD (3%), compared with the general population. 
Neuropsychological and mental health sequalae 
have been described after CHS, even among non-
operated patients.30,31 In our material, we found no 
correlation between the prevalence of psychiatric 
disorders and suicides. However, our data did not 
include antidepressants, because the special reim-
bursement right for depression requires psychotic 
symptoms to be granted, thus leaving out an im-
portant psychiatric disorder from the scope of the 
study. Moreover, it is recognized that specifically syn-
dromes characterized by a combination of cardiac 
defects, abnormal facial features, thymic hypoplasia, 
cleft palate, and hypocalcemia (CATCH 22) predis-
poses to psychosis later in life.32 In the current study, 
however, we did not have data on the incidence of 
CATCH- 22. Nevertheless, these results underscore 
the importance of screening for mental health disor-
ders among both simple and severe defects.
Endocrine disorders were more common among 
the patient population. Hypogonadism and the need 
for growth hormone were particularly common 
among patients with COA. Coexisting congenital 
chromosomal defects and anomalies, such as Turner 
syndrome, can most likely explain most of these 
cases.
Finally, cancer is an increasingly recognized mor-
bidity after CHS.33 Our material revealed a higher in-
cidence for the need of cancer medications among 
patients with ASD compared with the general popu-
lation. However, chemotherapies are mostly admin-
istered in a hospital setting and not purchased by 
patients, which excludes them from our data. As such, 
the full scope of cancer incidence among patients 
and the general population remains unknown in our 
material.
LIMITATIONS
First, the current study did not include patients who 
only underwent catheter interventions. Second, in-
formation on special reimbursement entitlements, 
although informative, does not reflect the actual in-
cidence and prevalence of disease, particularly if left 
undiagnosed or untreated. Third, this study does not 
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include medications that are not part of the special 
reimbursement program, such as antidepressants, 
antibiotics, and other relatively short- term medication 
regimens for commonly short- term curable diseases. 
Fourth, some medications that are administered in 
controlled hospital settings, such as cancer medi-
cations, were not included in this study. Thus, some 
diseases, particularly certain cancer types, may be 
underrepresented in the current data. Fifth, the spe-
cial reimbursement data do not take into account the 
difference in practice among physicians, especially 
on the diagnosis used to apply for special reimburse-
ment for a certain medication. This is particularly true 
for medications used for a multitude of indications, 
such as angiotensin- converting enzyme inhibitors 
and β blockers, which could be applied for special 
reimbursement under the diagnosis of hypertension 
or chronic heart failure. Sixth, some patient groups 
receive special reimbursement entitlements routinely 
postoperatively for certain cardiovascular medications, 
such as heart failure medication for single- ventricle 
morphological features, skewing the results. Seventh, 
several disorders may be treated nonpharmacologi-
cally, such as surgical comorbidity and disorders re-
quiring psychotherapy or physical therapy. Finally, we 
have to acknowledge a possible selection bias and 
procedure bias because of the possibility of patients 
with CHDs having a higher probability of timely diag-
nosis and prescription of reimbursed medications be-
cause of their medical history and regular follow- up.
CONCLUSIONS
In conclusion, both cardiac and noncardiac chronic 
morbidity is common after pediatric CHS. More im-
portant, both simple and severe defects remain at 
significant risk for late morbidity, underscoring the im-
portance of longitudinal follow- up in all patients after 
CHS.
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Table S1. List of diseases with accepted special reimbursement entitlements in Finland 
categorized by disease group. 
 
Cardiovascular 
Atrial fibrillation 
Chronic arrhythmia 
Chronic heart failure 
Clopidogrel 
Coronary artery syndrome and associated dyslipidemia 
Hypertension 
Pulmonary hypertension 
Dermatological 
Generalized eryhtrodermia 
Psoriasis 
Severe dermatitis 
Endocrine 
Adrenal insufficiency 
Diabetes insipidus 
Diabetes type 2 
Diabetes, insulin 
Disorder in vitamin D metabolism 
Dyslipidemia 
Familial dyslipidemia 
Growth hormone 
Hypogonadism 
Hypoparathyroidism 
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Hypopituitarism 
Hypothyroidism 
Osteoporosis 
Primary or secondary hyperparathyreosis 
Severe pancreatic deficiency 
Gastrointestinal 
Inflammatory bowel disease 
Hematological 
Aplastic anemia 
Chronic coagulation disorders 
Gammaglobulin deficiency 
Isolated thrombocytopenia or granulocytopenia 
Pernicious anemia / vB12 deficiency 
Malignancies 
Breast cancer 
Cancer 
Chronic myeloid leukemia or CLL 
GIST, renal, or pancreatic cancer 
Gynecological cancer 
Hematologic cancer 
Hematologic cancers 
Hepatic, renal, or thyroid cancer 
Melanoma and renal carcinoma 
Non-small cell lung cancer and pancreatic cancer 
Other malignancies 
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Prostate cancer 
Renal, pancreatic, breast cancer or tuberous sclerosis-associated astrocytoma 
Renal, pancreatic, or breast cancer 
Metabolic 
Obesity 
Nephrological 
Anemia related to chronic kidney failure 
Chronic renal failure 
Renal failure 
Uremia requiring dialysis 
Neurologic 
Dementia (parkinson's or alzheimer) 
Epilepsy 
Epilepsy or other seizures 
Multiple sclerosis 
Myasthenia gravis 
Narcolepsy 
Parkinson's disease 
Parkinsonism 
Other 
Anxiety related to mental disability 
Congenital metabolic diseases 
Cow milk protein allergy 
Daily enteral feeding 
Erectile dysfunction 
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Glaucoma 
Hyperuricemia 
Malabsorbance 
Neuralgia 
Secondary anemias (several) 
Severe malnutrition 
Psychiatric 
ADHD 
Alcohol or opioid addiction 
Antipsychotic 
Opioid addiction 
Psychosis 
Pulmonary 
Chronic obstructive pulmonary disease 
Rheumatic 
Gout 
Rheumatic disease 
Sarcoidosis 
Transplantation 
Immunosuppressant 
Medications status post-transplantation 
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Table S2. Surgical data on select defect groups.  
Defect 1960s 1970s 1980s 1990s 2000s All 
COA, n (%) 
96 
(100) 
346 
(100) 
330 
(100) 
305 
(100) 
224 
(100) 
1301 
(100) 
Operative technique 
      
End-to-end 91 (95) 297 (86) 235 (71) 218 (71) 186 (83) 1027 (79) 
Subclavian flap 0 (0) 4 (1) 72 (22) 69 (23) 1 (0) 146 (11) 
Other 5 (5) 33 (9) 13 (4) 4 (1) 6 (3) 61 (5) 
Patch aortoplasty 0 (0) 10 (3) 5 (2) 2 (1) 11 (5) 28 (2) 
Extended end-to-
end 0 (0) 0 (0) 0 (0) 8 (3) 19 (9) 27 (2) 
Unknown 0 (0) 2 (1) 4 (1) 3 (1) 0 (0) 9 (1) 
Interposition graft 0 (0) 0 (0) 1 (0) 1 (0) 1 (0) 3 (0) 
VSD, n (%) 
60 
(100) 
215 
(100) 
348 
(100) 
499 
(100) 
306 
(100) 
1428 
(100) 
Defect type 
      
Single 58 (97) 196 (91) 304 (87) 402 (81) 263 (86) 1223 (86) 
Multiple 1 (2) 9 (4) 32 (9) 66 (13) 36 (12) 144 (10) 
Other 1 (2) 10 (5) 12 (3) 31 (6) 7 (2) 61 (4) 
TOF, n (%) 
47 
(100) 
107 
(100) 
142 
(100) 
155 
(100) 
136 
(100) 
587 (100) 
Operative technique 
      
Primary 6 (13) 80 (75) 117 (82) 115 (74) 109 (80) 427 (73) 
Staged 41 (87) 27 (25) 25 (18) 40 (26) 22 (16) 155 (26) 
Other 0 (0) 0 (0) 0 (0) 0 (0) 5 (4) 5 (1) 
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TGA, n (%) 
12 
(100) 92 (100) 
136 
(100) 
133 
(100) 
126 
(100) 499 (100) 
Defect type 
      
TGA, IVS 3 (25) 59 (64) 76 (56) 71 (53) 78 (62) 287 (58) 
TGA, VSD 5 (42) 21 (23) 32 (24) 36 (27) 28 (22) 122 (24) 
DORV, TGA type 0 (0) 2 (2) 16 (12) 14 (11) 13 (10) 45 (9) 
TGA, VSD, 
LVOTO 3 (25) 2 (2) 5 (4) 8 (6) 2 (2) 20 (4) 
Other 1 (8) 5 (6) 2 (1) 2 (1) 2 (2) 12 (1) 
TGA, IVS, 
LVOTO 0 (0) 3 (3) 4 (3) 2 (2) 0 (0) 9 (2) 
CCTGA 0 (0) 0 (0) 1 (0) 0 (0) 3 (2) 4 (1) 
Operative technique 
      
ASO 0 (0) 0 (0) 18 (13) 115 (87) 117 (93) 250 (50) 
Senning 0 (0) 12 (13) 105 (77) 5 (4) 0 (0) 122 (24) 
Mustard 2 (17) 70 (76) 1 (1) 0 (0) 0 (0) 73 (15) 
Other or unknown 8 (67) 6 (7) 5 (4) 3 (2) 7 (5) 29 (6) 
Rastelli 2 (17) 4 (4) 7 (5) 10 (7) 2 (2) 25 (5) 
COA, coarctation of the aorta; VSD, ventricular septal defect; TOF, tetralogy of Fallot; TGA, 
transposition of the great arteries; IVS, intact ventricular septum; DORV, double-outlet right 
ventricle; LVOTO, left ventricular outflow tract obstruction; CCTGA, congenitally corrected 
transposition of the great arteries. 
  
D
ow
nloaded from
 http://ahajournals.org by on June 25, 2020
Table S3. Number of patients with special reimbursement entitlements by defect severity 
and disease group.  
  Simple, n (%) 
Severe, n 
(%) Miscellaneous, n (%) All, n (%) 
Metabolic 6 (0.1) 0 (0.0) 0 (0.0) 6 (0.1) 
Hematological 5 (0.1) 2 (0.1) 3 (0.2) 10 (0.1) 
Nephrological 9 (0.2) 0 (0.0) 1 (0.1) 11 (0.1) 
Dermatologic 18 (0.3) 3 (0.2) 6 (0.4) 27 (0.3) 
Gastrointestinal 37 (0.7) 4 (0.3) 7 (0.4) 48 (0.6) 
Malignancies 46 (0.8) 2 (0.1) 10 (0.6) 58 (0.7) 
Transplantation 13 (0.2) 23 (1.6) 27 (1.7) 63 (0.7) 
Rheumatic 71 (1.3) 18 (1.2) 27 (1.7) 116 (1.3) 
Sarcoidosis 3 (0.1) 0 (0.0) 0 (0.0) 3 (0.0) 
Gout 2 (0.0) 2 (0.1) 2 (0.1) 6 (0.1) 
Other rheumatic disease 66 (1.2) 16 (1.1) 25 (1.6) 107 (1.9) 
Psychiatric 143 (2.5) 17 (1.2) 29 (1.8) 189 (2.2) 
Alcohol or opioid addiction 5 (0.1) 0 (0.0) 1 (0.1) 6 (0.1) 
ADHD 6 (0.1) 1 (0.1) 4 (0.3) 11 (0.1) 
Psychosis 132 (2.4) 16 (1.1) 24 (1.5) 172 (2.0) 
Neurological 173 (3.1) 53 (3.7) 65 (4.1) 291 (3.4) 
Myasthenia gravis 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 
Other neurological 4 (0.1) 0 (0.0) 0 (0.0) 4 (0.0) 
Multiple sclerosis 9 (0.2) 1 (0.1) 0 (0.0) 10 (0.1) 
Epilepsy 159 (2.8) 52 (3.6) 65 (4.1) 276 (3.2) 
Other diseases 202 (3.6) 152 (10.6) 169 (10.7) 523 (6.1) 
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Glaucoma 23 (0.4) 4 (0.3) 11 (0.7) 38 (0.4) 
Anxiety related to mental illness 30 (0.5) 3 (0.2) 18 (1.1) 51 (0.6) 
Other 149 (2.6) 145 (10.1) 140 (8.9) 434 (5.0) 
Endocrine 314 (5.6) 52 (3.6) 127 (8.0) 493 (5.7) 
Diabetes type 2 2 (0.0) 0 (0.0) 1 (0.1) 3 (0.0) 
Hypoparathyroidism 4 (0.1) 4 (0.3) 4 (0.3) 12 (0.1) 
Other endocrine 19 (0.3) 2 (0.1) 8 (0.5) 29 (0.3) 
Growth hormone 17 (0.3) 4 (0.3) 13 (0.8) 34 (0.4) 
Hypopituitarism 33 (0.6) 7 (0.5) 21 (1.3) 61 (0.7) 
Hypogonadism 52 (0.9) 2 (0.1) 14 (0.9) 68 (0.8) 
Hypothyroidism 77 (1.4) 15 (1.0) 49 (3.1) 141 (1.6) 
Insulin-treated diabetes 110 (2.0) 18 (1.3) 17 (1.1) 145 (1.7) 
Obstructive pulmonary disease 490 (8.7) 113 (7.8) 160 (10.1) 763 (8.8) 
Cardiovascular 1008 (18.0) 758 (52.6) 632 (40.0) 2398 (27.8) 
Other cardiovascular 1 (0.0) 3 (0.2) 1 (0.1) 5 (0.1) 
Dyslipidemia 3 (0.1) 4 (0.3) 1 (0.1) 8 (0.1) 
Coronary artery syndrome 9 (0.2) 15 (1.0) 9 (0.6) 33 (0.4) 
Arrhythmia 84 (1.5) 126 (8.8) 64 (4.1) 274 (3.2) 
Hypertension 266 (4.7) 35 (2.4) 49 (3.1) 350 (4.1) 
Heart failure 645 (11.5) 575 (39.9) 508 (32.2) 1728 (20.0) 
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